Evidence mapPaperPMID 21737787Full record

Trial reportCirculation research2011

Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Douglas W Losordo, Timothy D Henry, Charles Davidson, Joon Sup Lee, Marco A Costa, Theodore Bass, Farrell Mendelsohn, F David Fortuin, Carl J Pepine, Jay H Traverse and 9 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Circulation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00300053 (A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia), which is not on this map. Cited by 227 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 8 pooled it
53.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00300053 phase2completednot on this map

A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)

TypeinterventionalSponsorLisata Therapeutics, Inc.Ran2006 to 2009Enrolled321ConditionsMyocardial IschemiaArmsCLBS14 (low-dose), CLBS14 (high-dose), placebo injection
3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 8 syntheses or guidelines pooled it, 488 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Douglas W LosordoDivision of Cardiology, Northwestern Memorial Hospital, Northwestern University, Chicago, IL 60611, USA. d-losordo@northwestern.edu
Timothy D Henry
Charles Davidson
Joon Sup Lee
Marco A Costa
Theodore Bass
Farrell Mendelsohn
F David Fortuin
Carl J Pepine
Jay H Traverse
David Amrani
Bruce M Ewenstein
Norbert Riedel
Kenneth Story
Kerry Barker
Thomas J Povsic
Robert A Harrington
Richard A Schatz
ACT34-CMI Investigators
Mayo Clinic in Arizona · USDuke University · USUniversity of Florida · USAbbott Northwestern Hospital · USAngiogenesis Foundation · USCase Western Reserve University · USClinical Research Institute · USMinneapolis Heart Institute Foundation · USUniversity Hospitals Case Medical Center · US

Funding

THERAPEUTIC ANGIOGENESIS IN VASCULAR MEDICINE IIR01HL053354 · CARITAS ST. ELIZABETH'S MEDICAL CENTER · 1995 to 2004
$983k
NHLBI NIH HHS P01 HL108795NHLBI NIH HHS R01 HL053354NHLBI NIH HHS R01 HL077428NHLBI NIH HHS R01 HL080137NHLBI NIH HHS R01 HL095874
6 · The paper itself

Abstract

rationaleA growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function.

objectiveEvaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options. METHODS AND

resultsIn this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1×10(5) or 5×10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8±1.1 versus 10.9±1.2, P=0.020) and 12 months (6.3±1.2 versus 11.0±1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139±151 versus 69±122 seconds, P=0.014; 12 months: 140±171 versus 58±146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients.

conclusionsPatients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies.

Indexed as

Coronary CirculationHematopoietic Stem Cell TransplantationMicrocirculationAgedAngina PectorisAntigens, CD34BiomarkersBlood Component RemovalCardiovascular AgentsDouble-Blind MethodEndothelial CellsExercise TestExercise ToleranceFemaleHematopoietic Stem Cell MobilizationHumansAntigens, CD34BiomarkersCardiovascular Agents

Identifiers

PMID21737787
PMCPMC3190575
OpenAlexW2111004371

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.